Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
Praxis Precision Medicines, Inc.
A biopharmaceutical company developing treatments for brain disorders like epilepsy and essential tremor, using two platforms—Cerebrum for small-molecule drugs and Solidus for antisense oligonucleotide therapies. Its lead candidates include ulixacaltamide for essential tremor and seizure-fighting drugs like relutrigine. Founded in 2015 as EpiPM Therapeutics, it took its name from the Greek "praxis," meaning "to do"—turning scientific theory into practical treatment.
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
8.01 Other Events
4.01 Changes in Registrant's Certifying Accountant · 9.01 Financial Statements and Exhibits
8.01 Other Events
8.01 Other Events
5.07 Submission of Matters to a Vote of Security Holders
8.01 Other Events
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits